MARCHON EYEWEAR EXTENDS EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH NIKE

MARCHON EYEWEAR EXTENDS EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH NIKE

Thursday, June 4 2015 | 00 h 00 min | Press Release

Melville, NY – Marchon Eyewear, Inc. is pleased to announce the long-term extension of its licensing agreement with Nike, Inc. for the exclusive design, production and worldwide distribution of Nike optical and sunglass collections.

Claudio Gottardi, President and CEO of Marchon Eyewear, commented: “We’re extremely proud to continue our successful partnership with Nike. This unrivaled brand is constantly at the forefront of sports technology and innovation, therefore pushing our design team to continue striving to develop new groundbreaking ideas and high-quality products. We are confident that with the renewal of our long-standing partnership, which dates back to 1999, we can achieve further success with the Nike eyewear collections.”

For more information about Nike Vision, visit http://www.nikevision.com/.

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

MARCHON EYEWEAR EXTENDS EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH NIKE

Featured Posts